These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 10870982)

  • 1. What is the true solubility advantage for amorphous pharmaceuticals?
    Hancock BC; Parks M
    Pharm Res; 2000 Apr; 17(4):397-404. PubMed ID: 10870982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Solubility advantage of amorphous pharmaceuticals: I. A thermodynamic analysis.
    Murdande SB; Pikal MJ; Shanker RM; Bogner RH
    J Pharm Sci; 2010 Mar; 99(3):1254-64. PubMed ID: 19697391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Solubility advantage of amorphous pharmaceuticals: II. Application of quantitative thermodynamic relationships for prediction of solubility enhancement in structurally diverse insoluble pharmaceuticals.
    Murdande SB; Pikal MJ; Shanker RM; Bogner RH
    Pharm Res; 2010 Dec; 27(12):2704-14. PubMed ID: 20859662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preparation of an amorphous sodium furosemide salt improves solubility and dissolution rate and leads to a faster Tmax after oral dosing to rats.
    Nielsen LH; Gordon S; Holm R; Selen A; Rades T; Müllertz A
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):942-51. PubMed ID: 24075980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amino acids as co-amorphous stabilizers for poorly water soluble drugs--Part 1: preparation, stability and dissolution enhancement.
    Löbmann K; Grohganz H; Laitinen R; Strachan C; Rades T
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):873-81. PubMed ID: 23537574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Solubility advantage of amorphous pharmaceuticals, part 3: Is maximum solubility advantage experimentally attainable and sustainable?
    Murdande SB; Pikal MJ; Shanker RM; Bogner RH
    J Pharm Sci; 2011 Oct; 100(10):4349-56. PubMed ID: 21630280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicted amorphous solubility and dissolution rate advantages following moisture sorption: Case studies of indomethacin and felodipine.
    Skrdla PJ; Floyd PD; Dell'Orco PC
    Int J Pharm; 2019 Jan; 555():100-108. PubMed ID: 30448307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physical stability and solubility advantage from amorphous celecoxib: the role of thermodynamic quantities and molecular mobility.
    Gupta P; Chawla G; Bansal AK
    Mol Pharm; 2004; 1(6):406-13. PubMed ID: 16028352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolution of supersaturation of amorphous pharmaceuticals: nonlinear rate of supersaturation generation regulated by matrix diffusion.
    Sun DD; Lee PI
    Mol Pharm; 2015 Apr; 12(4):1203-15. PubMed ID: 25775257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Solubility Advantage (and Disadvantage) of Pharmaceutical Amorphous Solid Dispersions.
    Huang S; Mao C; Williams RO; Yang CY
    J Pharm Sci; 2016 Dec; 105(12):3549-3561. PubMed ID: 27692620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting the Solubility Advantage of Amorphous Pharmaceuticals: A Novel Thermodynamic Approach.
    Paus R; Ji Y; Vahle L; Sadowski G
    Mol Pharm; 2015 Aug; 12(8):2823-33. PubMed ID: 26107071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic in vitro and in vivo evaluation for determining the feasibility of making an amorphous solid dispersion of a B-Raf (rapidly accelerated fibrosarcoma) inhibitor.
    Cui Y; Chiang PC; Choo EF; Boggs J; Rudolph J; Grina J; Wenglowsky S; Ran Y
    Int J Pharm; 2013 Sep; 454(1):241-8. PubMed ID: 23834830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of Accuracy of Amorphous Solubility Advantage Calculation by Comparison with Experimental Solubility Measurement in Buffer and Biorelevant Media.
    Zhang W; Haser A; Hou HH; Nagapudi K
    Mol Pharm; 2018 Apr; 15(4):1714-1723. PubMed ID: 29522344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Amorphous Drug Stability Predictions Using Easily Calculated, Predicted, and Measured Parameters.
    Nurzyńska K; Booth J; Roberts CJ; McCabe J; Dryden I; Fischer PM
    Mol Pharm; 2015 Sep; 12(9):3389-98. PubMed ID: 26236939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting the solubility enhancement of amorphous drugs and related phenomena using basic thermodynamic principles and semi-empirical kinetic models.
    Skrdla PJ; Floyd PD; Dell'Orco PC
    Int J Pharm; 2019 Aug; 567():118465. PubMed ID: 31279056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the mechanical properties of the crystalline and amorphous forms of a drug substance.
    Hancock BC; Carlson GT; Ladipo DD; Langdon BA; Mullarney MP
    Int J Pharm; 2002 Jul; 241(1):73-85. PubMed ID: 12086723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aqueous solubility of crystalline and amorphous drugs: Challenges in measurement.
    Murdande SB; Pikal MJ; Shanker RM; Bogner RH
    Pharm Dev Technol; 2011 Jun; 16(3):187-200. PubMed ID: 20429826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation of hydrate forms of paroxetine HCl from the amorphous state: an evaluation of thermodynamic and experimental predictive approaches.
    Pina MF; Pinto JF; Sousa JJ; Craig DQ; Zhao M
    Int J Pharm; 2015 Mar; 481(1-2):114-24. PubMed ID: 25592956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro and in vivo comparison between crystalline and co-amorphous salts of naproxen-arginine.
    Kasten G; Lobo L; Dengale S; Grohganz H; Rades T; Löbmann K
    Eur J Pharm Biopharm; 2018 Nov; 132():192-199. PubMed ID: 30266670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Solubility of crystalline organic compounds in high and low molecular weight amorphous matrices above and below the glass transition by zero enthalpy extrapolation.
    Amharar Y; Curtin V; Gallagher KH; Healy AM
    Int J Pharm; 2014 Sep; 472(1-2):241-7. PubMed ID: 24968139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.